Recursion Pharma CBO Virani transitions to Senior Strategic Advisor; Kinn joins exec team

RECURSION PHARMACEUTICALS, INC.

Dr. Shafique Virani stepped down as Chief Business Officer effective Feb 6, 2024, to become Senior Strategic Advisor.
Matthew Kinn, previously SVP Business Development, assumes all CBO responsibilities on Recursion's executive team.
Virani receives advisory fees of $1,000/hour (min $25k/month Feb–Jul, then $15k/month) and continued equity vesting.
If terminated before Aug 1, 2024, Virani gets a lump sum starting at $390k (Feb) decreasing $65k/month.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Shafique Virani

Senior Strategic Advisor

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2024-02-06
Successor: Matthew Kinn
Filed: February 7, 2024, 6:59 PM ET

Dr. Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals, Inc. (the “Company” or “Recursion”) transitioned into a new role as a Senior Strategic Advisor.

Appointed

Matthew Kinn

Chief Business Officer

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2024-02-06
Filed: February 7, 2024, 6:59 PM ET

Matthew Kinn, Senior Vice President, Business Development and Corporate Initiatives joined Recursion’s executive team and assumed all responsibilities previously held by Dr. Virani.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shafique Virani changed role as Senior Strategic Advisor at RECURSION PHARMACEUTICALS, INC..

Action: transitioned
Role: Senior Strategic Advisor

Exact text from the filing

Dr. Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals, Inc. (the “Company” or “Recursion”) transitioned into a new role as a Senior Strategic Advisor.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Kinn was appointed as Chief Business Officer at RECURSION PHARMACEUTICALS, INC..

Action: joined
Role: Chief Business Officer

Exact text from the filing

Matthew Kinn, Senior Vice President, Business Development and Corporate Initiatives joined Recursion’s executive team and assumed all responsibilities previously held by Dr. Virani.

View on SEC.gov

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.